"Endeavors" publishes article charting UNC-Chapel Hill's long involvement in bleeding disorders research and treatment
"Endeavors" magazine, which writes about research and creative activity at UNC-Chapel Hill, published an article in its July issue about UNC-Chapel Hill's history of research and treatment for blood disorders, which began in 1947 under Dr. Kenneth Brinkhous. His seminal work set the stage for major breakthroughs in hemophilia and HIV.
Kovaltry is designed to reduce bleeding in patients with hemophilia A when infused prophylactically two or three times per week, and was approved by the European Commission on Feb. 22.
Patients can go up to two weeks between infusions.
George McCoy, a longtime patient at the UNC Hemophilia & Thrombosis Center and the first man in the world to receive recombinant clotting factor, was the subject of a news story on WTVD on February 16.
UNC's 340B pharmacy's accreditation by URAC became effective February 1, 2016. URAC's mission is to promote continuous improvement in the quality and efficiency of health care management through processes of accreditation, education, and measurement.
In a press release dated January 19, 2016, the International Society on Thrombosis and Haemostasis (ISTH) announced its new international clinical Core Curriculum on thrombosis and hemostasis, the first framework of its kind to define the minimum standards for a medical doctor to attain a level of proficiency to enable them to practice independently as specialists in the field.
Nigel Key, M.D., Director of the UNC Hemophilia and Thrombosis Center, is extensively quoted in the January 12, 2016 WebMD article "Hemophilia: New Treatments for an Old Disease," by Sonya Collins.
Brenda Nielsen, RN, nurse in the UNC Comprehensive Hemophilia Diagnostic and Treatment Center, will serve a three-year term on this council beginning December 1, 2015 through November 30, 2018.
On October 17, The UNC TarHealers walk team raised $5,160 for the Raleigh Hemophilia Walk, which benefits Hemophilia of North Carolina and the National Hemophilia Foundation.
Dr. Key's lecture, which was delivered on Monday, October 19, 2015, was entitled "Thrombosis in Hemolytic Anemias: What are the Common Themes?"
Alice Ma, MD, associate professor, department of medicine, division of hematology-oncology, delivered this year's Whitehead Lecture on August 19. The themes of Ma’s lecture closely followed its title: “Endurance, Obstacles, Perseverance and Joy: My Transformation from the World’s Crummiest Medical Student to Faculty at the World’s Best Medical School.”
The 8th Symposium on Hemostasis: Translational and Basic Science Discoveries will be held May 12-24, 2016 in Chapel Hill, North Carolina.
Research showed that bleeding events were drastically decreased in animals with hemophilia B. Using a viral vector to swap out faulty genes proved safe and could be used for the more common hemophilia A.
Nigel Key to deliver MacFarlane Biggs Lecture at British Society for Haemostasis and Thrombosis Annual Scientific Meeting in April
Nigel Key, MD, Director of the UNC Hemophilia and Thrombosis Center, has been invited to deliver a state-of-the-art lecture at the British Society for Haematology Annual Scientific Meeting on April 20, 2015.
UNC's Stephan Moll, MD comments on FDA approval of edoxaban (Savaysa) for atrial fibrillation, DVT, and PE
On Friday, January 9, the Food and Drug Administration approved edoxaban (Savaysa) as the fourth new oral anticoagulant (NOAC), giving it an indication in nonvalvular atrial fibrillation for renally impaired patients and in treating deep vein thrombosis and pulmonary embolism.
"Factor VIII inhibitory antibody in a patient with combined factor V/factor VIII deficiency," a letter to the editor of the journal "Haemophilia" by UNC-Chapel Hill hematologists Tyler Buckner, MD, Brenda Nielsen, MSN, Nigel Key, MD, and Alice Ma, MD, was published online on December 4, 2014.
Gene therapy developed at St. Jude Children's Research Hospital, University College London (UCL) and the Royal Free Hospital has transformed life for men with a severe form of hemophilia B by providing a safe, reliable source of the blood clotting protein Factor IX that has allowed some to adopt a more active lifestyle, researchers reported. The results appear in the November 20 edition of The New England Journal of Medicine.
On October 23, 2014, the U.S. Food and Drug Administration approved Obizur [Antihemophilic Factor (Recombinant), Porcine Sequence] for the treatment of bleeding episodes in adults with acquired hemophilia A (acquired Factor VIII [FVIII] deficiency).
On September 12, 2014, the United States Food and Drug Administration (FDA) approved Baxter International Inc.'s RIXUBIS for routine prophylactic treatment, control and prevention of bleeding episodes, and perioperative management in children with hemophilia B.